Indwara ya Catipropique Antiphospholipid (Indwara ya CAPS / Asherson): Inkubi y'umuyaga wa Microvascular Thrombose mu cyumweru kimwe no kuvura gatatu hamwe na Plasmapheresis¶

** Indwara ya Catipropique Antiphospholipid Syndrome (CAPS, nanone mu buryo butazwi nka Asherson's Syndrome nyuma ya Dr. Ronald Asherson, wabisobanuye bwa mbere mu 1992) ** ni bwo buryo bwuzuye, bwangiza ubuzima bwa ** Syndrome ya Antiphospholipid (APS) **, gukubita munsi 1 percent y'abarwayi ba APS (with nearly 50 percent of cases occurring as the very first clinical presentation in a patient who never knew they had APS). Mugihe APS ya kera isanzwe itera imiyoboro minini nini yimitsi cyangwa arterial (such as a single deep vein thrombosis, pulmonary embolism, or stroke) cyangwa gutakaza inda inshuro nyinshi, ** CAPS nigisasu giturika, cyuzuzanya-cyongerewe "umuyaga wa trombotic" (Thrombotic Microangiopathy [TMA] syndrome ya sisitemu yo gutwika [SIRS]) ** icyarimwe ikubiyemo microvessels ntoya ya ** sisitemu eshatu cyangwa nyinshi zingingo zitarenze iminsi 7 **, cyane cyane impyiko ** (73%: hypertension malignant, proteinuria, no kunanirwa gukabije kwimpyiko) **, ** ibihaha (60%: ARDS, embolism yimpaha, no gukwirakwiza amaraso ya alveolar) **, ** ubwonko (56%: ubwonko, gufatwa, ubwonko bwubwonko bwitwa trombose, na encephalopathie) **, ** umutima (50%: micro-infarction ya myocardial na Libman-Sacks valve ibimera) **, ** uruhu (47%: livedo racemosa, ischemia ibabaza ya digitale, na necrosis ya cutaneous) **, na ** glande ya adrenal (bilateral adrenal hemorrhage/infarction causing refractory hypotensive shock) **. Kuberako CAPS itwarwa nuburyo ** "Babiri-Hit" **, aho preexisting-titer ** antifospholipid antibodies (Lupus Anticoagulant [LA], Anti-Cardiolipin [aCL] IgG/IgM, na Anti-Beta-2-Glycoprotein-I [aB2GPI] IgG/IgM) ** gutwikwa na acute "Second Hit" imbarutso (bacterial or viral infection in 49%, surgical procedures or trauma in 17%, abrupt withdrawal or subtherapeutic INR of Warfarin, malignancy, pregnancy/puerperium, or oral contraceptive estrogen), gutinda kwivuza bitwara **80 to 90 percent igipimo cy'impfu **, mugihe ICU yahise itangiza ** CAPS "Ubuvuzi butatu" ** igabanya impfu mo kabiri. Niba umurwayi ufite Lupus uzwi (SLE), Indwara ya Antiphospholipid, cyangwa trombocytopenia idasobanutse itera ibimenyetso bitunguranye byingingo nyinshi (shortness of breath, confusion, chest or flank pain, mottled purple skin, or dark/absent urine), hamagara aho utuye nimero yihutirwa ako kanya. Ongera usubiremo ubuyobozi bwa mugenzi wawe kuri ikibazo cya adrenal hamwe na inshinge yindwara ya Addison, gufata eclampsia, syndrome ya HELLP, na preeclampsia nyuma yo kubyara, na sepsis na septique.

Ishami ryihutirwa ryihutirwa hamwe na ICU byihutirwa ni ** gutangiza icyarimwe "CAPS Triple Therapy" icyarimwe mugihe cya mbere cyamavuriro yakekaga mikorobe-mikorobe myinshi (trombose) (WITHOUT waiting days for confirmatory antiphospholipid antibody titers or tissue biopsy) **: ** (1) Ubuvuzi bwimitsi itavanze Heparin (UFH) ** (not only to halt fibrin clot propagation, but because heparin directly inhibits complement activation [C3/C5 convertase]), ** (2) Dose-Yinshi Yinjiza Corticosteroide (Methylprednisolone 500 to 1,000 mg/day IV for 3 days, followed by 1 to 2 mg/kg/day) ** (to extinguish the NF-kappa-B endothelial cytokine storm), na ** (3) Ako kanya Ubuvuzi bwa Plasma buri munsi (Plasmapheresis / TPE guhana umubumbe wa 1.0 kugeza kuri 1.5 kurwanya plasma nshya ya Frozen Frozen / Albumin) NA / CYANGWA CYANE CYANE Immunoglobulin (IVIG, 0.4 g/kg/day IV for 5 days) , mugihe uvura imbarutso yanduye hamwe na antibiyotike yagutse kandi ugakoresha ** anti-C5 terminal yuzuza inhibitor Eculizumab (Soliris) cyangwa kurwanya CD20 Rituximab kubibazo byo kwanga.

Kora ubu¶

1. ** Hamagara numero yawe yihutirwa cyangwa utere ako kanya ICU / Hematology / Rheumatology Igisubizo cyihuse niba umurwayi arwaye trombose icyarimwe cyangwa imikorere mibi yumubiri muri >= 2 to 3 ingingo mugihe cyicyumweru. ** Hamagara 911 muri Amerika no muri Kanada, 999 mu Bwongereza, 112 hirya no hino mu muryango w’ubumwe bw’ibihugu by’Uburayi, 000 muri Ositaraliya, cyangwa ubaze ububiko bwacu bwa nimero yihutirwa. Wibuke ko **46 to 50 percent y'abarwayi ba CAPS NTA kwisuzumisha mbere ya APS cyangwa Lupus (SLE) ** mbere yo kwinjira mucyumba cyihutirwa.
2. ** Tangira Inkingi ya 1 ya CAPS Ubuvuzi butatu Ako kanya: Ubuvuzi bwimitsi itavanze Heparin (UFH) ((Even in the Presence of Moderate Thrombocytopenia or Diffuse Alveolar Hemorrhage). **
3. Heparin idakuweho ni itegeko ryibanze rya CAPS kubaho (reducing mortality from > 75% to about 30% muri International CAPS Registry) haba binyuze muri antithrombin-yunganirwa na anticoagulation hamwe na ** kubuza inzira za classique nibindi byuzuzanya **.
4. ** Isuzuma rikomeye rya Laboratoire Ikurikirana (The Lupus Anticoagulant aPTT Trap): ** Kuberako umurwayi azenguruka ** Lupus Anticoagulant (LA) ** antibodies zongerewe ubuhanga muburyo bwa fosifolipide ishingiye kumurongo aPTT (often to 60 to 100+ seconds * mbere * heparin itangiye), gukurikirana IV ya heparin idacometse hamwe nibisanzwe aPTT azagushuka muri ** bikabije munsi ya dose ya heparin **. ** Buri gihe ukurikirane IV Heparin idakuwe muri CAPS ukoresheje chromogenic Anti-Factor Xa (Anti-Xa) assay (target 0.3 to 0.7 IU/mL), NTAKIGEZE gisanzwe aPTT. **
5. ** Tangira Inkingi ya 2 ya CAPS Ubuvuzi butatu Ako kanya: Pulse Intravenous Methylprednisolone (500 to 1,000 mg IV Once Daily for 3 Consecutive Days, Bikurikiranye na 1 to 2 mg/kg/day IV).aB2GPI) ** ibikorwa bya endoteliyale NF-kappa-B na Tissue Factor imvugo kandi icyarimwe itwikiriye ** acute bilateral adrenal hemorhage / infarction ** (which complicates 13% to 26% of CAPS cases).
6. ** Tangira Inkingi ya 3 ya CAPS Ubuvuzi butatu mu masaha: Guhana kwa Plasma ya buri munsi (Plasmapheresis / TPE) NA / CYANGWA Dose-Imitsi Yinshi Immunoglobulin (IVIG). **
7. ** Kuvura Plasma yo kuvura (TPE, Umurongo wa mbere cyane cyane iyo Schistocytes / Microangiopathic Hemolytic Anemia [MAHA] cyangwa Kunanirwa kw'impyiko birahari): ** Guhana **1.0 to 1.5 plasma volumes buri munsi byibura iminsi 3 kugeza kuri 5 ** ukoresheje ** Plasma nziza ikonje (FFP) ** (cyangwa 50:50 FFP + 5% Albumin) gukuramo imashini aB2GPI na aCL autoantibodies, cytokine (IL-1, IL-6, TNF-alpha), no kuzuza ibice mugihe wuzuza anticagulants karemano (Antithrombin, Protein C, Protein S, and ADAMTS13).
8. ** Igipimo kinini IVIG (0.4 g/kg/day IV for 5 days cyangwa 1.0 g/kg/day for 2 days).never infuse IVIG right *before* a TPE session, or the apheresis machine will wash your expensive IVIG straight into the waste bag).
9. ** Higa Hanze kandi Ufate Uburakari "Icya kabiri-hit" Imvura igwa (Infection in 49% of Cases). Ntuzigere uhagarika anticoagulation mbere yo kubagwa kumurwayi uzwi wa Triple-Positive APS (always bridge closely with IV UFH or therapeutic LMWH).
10. ** Kohereza Terminal Yuzuza Kubuza (IV Eculizumab 900 mg Icyumweru) cyangwa Rituximab Kera hakiri kare CAPS cyangwa TMA izwi (Schistocytes + Severe Thrombocytopenia + Renal Failure). ** Ibimenyetso byubushakashatsi nubuvuzi byerekana ko CAPS ikabije itwarwa no guhunga ** Ikigo cyuzuye cyuzuye (C5b-9 membrane attack complex) ** gushira kuri selile endothelia (often with underlying complement regulatory gene mutations). Gutanga ** IV Eculizumab (Soliris) ** ihagarika imitsi yimitsi itwara imitsi, trombocytopenia, hamwe na mikorobe yimitsi yimpyiko mugihe cyamasaha 48 kugeza 72 mugihe ubuvuzi busanzwe butatu buhagije.

Igiti cyemezo: ukekwaho indwara ya Catastrophique Antiphospholipid Syndrome (CAPS / Asherson's Syndrome) na ICU Triple Therapy¶

flowchart TD
    Patient["Umurwayi Yerekana Byihuta Byihuta Byinshi-Imikorere idahwitse (> = Inzego 3 Mugihe cyiminsi 7): <br/> - Impyiko: Gukomeretsa Impyiko, HTN, Proteinuria Troponin, Microthrombi ya Myocardial <br/> - Uruhu: Livedo Racemosa, Digital Gangrene, Necrosis y'uruhu <br/> - Adrenal: Flank / Ububabare bw'inda + Hypotension"] --> StatWorkup["STAT Ibitanda & Laboratoire (Ntutinde Kuvura Ibisubizo bya Antibody): <br/> 1. Amavuta ya periferiya (Schistocytes), LDH, Haptoglobin, Platelets, Coags, Fibrinogen <br/> 2. Shushanya Lupus Anticoagulant (dRVVT / aPTT), Anti-Cardiolipin IgG / IgM, & Anti-Beta-2-Glycoprotein-I IgG / IgM (MBERE YO Guhana kwa Plasma) <br/> 3. Shushanya Cortisol Yisanzwe & ACTH (Reba kuri Adrenal Amaraso Yombi) + Igikorwa cya ADAMTS13 (Tegeka TTP)"]

    StatWorkup --> TripleTherapy["SHAKA EMPIRIC 'CAPS TRIPLE THERAPY' AKAZI MURI ICU"]

    TripleTherapy --> Pillar1["INKINGI 1: Ubuvuzi bwa IV butavunitse Heparin (UFH) <br/> - Gukurikirana cyane hamwe na Chromogenic ANTI-FACTOR Xa Urwego (Intego 0.3 kugeza 0.7 IU / mL)"]

    TripleTherapy --> Pillar2["INKINGI 2: Dose-Dort IV Corticosteroide <br/> - IV Methylprednisolone 500 kugeza 1.000 mg Buri munsi muminsi 3, Hanyuma 1 kugeza 2 mg / kg / kumunsi <br/> - Ifunga NF-kappa-B Inkubi y'umuyaga & Ikemura ibibazo bya Adrenal"]

    TripleTherapy --> Pillar3["INKINGI 3: Guhindura Plasma ya buri munsi (TPE) +/- Dose-Dose-IVIG <br/> - Guhana 1.0 kugeza 1.5 Umubumbe wa Plasma Buri munsi x 5+ Ukoresheje Plasma Nshya Yuzuye (FFP)"]

    Pillar1 --> TriggerAndRefractory{"Kuvura 'Second-Hit' Trigger (Empiric Broad-Spectrum Antibiotics niba hari infection) & Suzuma 24-kuri-48-Igisubizo"}
    Pillar2 --> TriggerAndRefractory
    Pillar3 --> TriggerAndRefractory

    TriggerAndRefractory -->|"Thrombocytopenia yangiritse, MAHA Schistocytes ikomeje, cyangwa kunanirwa kwingingo."| AddEculizumab["ESCALATE IMMEDIATELY:<br/>1. IV Eculizumab (Anti-C5 Complement Inhibitor: 900 mg IV Weekly x 4, Then 1,200 mg) [Give Meningococcal Vaccine + Ciprofloxacin/Penicillin Prophylaxis]<br/>2. IV Rituximab (375 mg/m2 Weekly x 4) to Deplete B-Cell Autoantibody Production"]

Igice cya 1: "Two-Hit" Pathophysiology ya Syndrome ya Asherson hamwe n'ibipimo mpuzamahanga byo gusuzuma¶

.¶

Abantu benshi bazenguruka imyaka myinshi bazenguruka ** "Triple-Positive" antiphospholipid antibodies ((Lupus Anticoagulant + Anti-Cardiolipin + Anti-Beta-2-Glycoprotein-I) ** udakuze amaraso ("The First Hit"). Kubera iki? Kuberako mubihe bisanzwe byo kuruhuka, selile endothelia selile ihisha membrane fosifolipide yuzuye nabi kurupapuro rwimbere, ikazenguruka ** Beta-2-Glycoprotein-I (B2GPI) ** ireremba muburyo bufunze buzenguruka bihisha antigenic binding domaine (Domain I).

• ** Imbarutso ya "Kanda ya kabiri" (Infection, Surgery, Trauma, Pregnancy, or Warfarin Withdrawal): **
• Iyo indwara (Gram-negative sepsis, respiratory virus, urinary tract infection).
• Kuzenguruka B2GPI ihambira kuri endotelium yangiritse hanyuma igapfundikanya muburyo bwa ** "J-ifi ya J-ifi" ihinduka **, ikerekana ** Domain I **.
• Indwara ya ** Indwara ya Beta-2-Glycoproteine-I (aB2GPI) IgG dimers ** kwambukiranya gufungura B2GPI molekile kuri selile ya endoteliyale, platine, na monocytes ikoresheje ** Toll-Like Receptor 4 (TLR4) ** na ** Umugereka A2 **, ukora NF-kappa-B na p38 MAPK.
• ** Kuzuza Amplification Loop (C3a / C5a / C5b-9): ** Urubibi aB2GPI ubudahangarwa bw'umubiri butera gukora cyane inzira ya ** Classical and Alternative Complement Inzira **, ikabyara anaphylatoxine C3a na C5a (which recruit neutrophils to extrude prothrombotic NETs) no gukubita **C5b-9 Membrane Attack Complex pores ** mumyanya mikorobe ya endoteliyale mikorobe mumpyiko, ibihaha, ubwonko, umutima, na glande ya adrenal.

2. Ibipimo ngenderwaho byibanze byerekana ibyiciro bya APS (Asherson et al. International Consensus)¶

Abaganga b’amavuriro bashyira umurwayi ko afite ** CAPS isobanutse ** (all 4 criteria) cyangwa ** Birashoboka CAPS ** (3 of 4 criteria) bishingiye kuri: 1. ** Ingingo ya 1 (>= 3 Organs, Systems, or Tissues): ** Ibimenyetso byamavuriro byerekana uruhare rwa ** ingingo eshatu cyangwa nyinshi, sisitemu, na / cyangwa tissue ** (renal, pulmonary, cerebral, cardiac, cutaneous, hepatic, gastrointestinal/mesenteric, splenic, or adrenal). 2. ** Ingingo ya 2 (<= 7 Days): ** Gutezimbere kwigaragaza kwa clinique ** icyarimwe cyangwa mugihe kitarenze icyumweru **. 3. ** Ingingo ya 3 (Histopathologic Microthrombosis): ** Kwemeza na histopathology ya ** gufunga inzabya nto (thrombotic microangiopathy) byibuze urugingo rumwe cyangwa tissue ** (typically via skin punch biopsy of livedo/necrotic lesions or renal biopsy once stabilized). 4. ** Ingingo ya 4 (Laboratory Antiphospholipid Antibodies): ** Kubaho kwa ** Lupus Anticoagulant (LA) **, ** Kurwanya Cardiolipine (aCL IgG / IgM kurwego rwo hejuru-hejuru > 40 GPL/MPL cyangwa > 99th percentile) **, na / cyangwa ** Kurwanya Beta-2-Glycoprotein-I (aB2GPI IgG / IgM) **.

• ** Igihe cyo Gusuzuma "CAPS Zishoboka" hanyuma ukahita uvura kuryama: ** Kuberako gukora biopsy yimpyiko kumurwayi urwaye cyane, anticoagulée, trombocytopenic ICU umurwayi wa ICU ni akaga kandi gutegereza ibyumweru 12 kugirango usubiremo antibody bidashoboka mugihe gikomeye, Ubwumvikane mpuzamahanga busobanura ** Birashoboka CAPS ** igihe cyose:
• Gusa ** ingingo 2 ** zirimo (with Criteria 2, 3, and 4 met), CYANGWA
• Ibipimo 4 byose byujujwe usibye ** histopathologic biopsy kwemeza yabuze ** (because the patient is too unstable/anticoagulated to biopsy), CYANGWA
• 3 organs kurwara trombose hejuru ya ** 1 kugeza 4 ibyumweru ** nubwo anticoagulation.
• ** Amategeko yubuvuzi: ** Kuvura ** Birashoboka CAPS ** bisa na ** CAPS Zisobanutse ** hamwe byuzuye ** Ubuvuzi butatu **.

Igice cya 2: Kuruhande-Kuruhande Gutandukanya Itandukaniro rya ICU Thrombotic Microangiopathies (CAPS vs. TTP vs. HUS/aHUS vs. HIT vs. Sepsis DIC)¶

Iyo umurwayi wa ICU arwaye platine igwa vuba, kwiyongera kwa creinine, urujijo rw'imitsi, hamwe na anemia ya hemolytic hamwe na ** schistocytes (helmet cells) ** kumena amaraso, gutandukanya ** CAPS ** na ** Thrombotic Thrombocytopenic Purpura (TTP) **, ** Indwara ya Hemolytic Uremic Syndrome (aHUS) **, ** HIT **, na ** Septic DIC ** ni ngombwa:

Part 3: Deep-Dive Into the 6 Organ Emergencies of CAPS (Including Bilateral Adrenal Hemorrhage & Diffuse Alveolar Hemorrhage)¶

When managing a CAPS patient in the ICU, clinicians must actively screen for and manage six signature organ crises that determine survival:

========================================================================
   THE 6 SIGNATURE MULTI-ORGAN THROMBOTIC CRISES OF CAPS (ASHERSON'S)
========================================================================

  1. RENAL TMA (73%):               2. PULMONARY CRISIS (60%):
     Renal interlobular/glomerular     ARDS, Pulmonary Embolism, AND
     capillary microthrombi ->         Capillaritis DIFFUSE ALVEOLAR
     Malignant HTN + Oliguric AKI.     HEMORRHAGE (DAH: Hemoptysis +
                                       Falling Hb + Ground-Glass CT).
  3. CEREBRAL / CNS (56%):             * CRITICAL PEARL: Even with DAH,
     Microvascular Encephalopathy,       continue carefully titrated IV
     Seizures, Ischemic Stroke, &        Heparin + Pulse Steroids + TPE.
     Cerebral Venous Sinus Clots.
                                    4. CARDIAC MICRO-INFARCTION (50%):
  5. CUTANEOUS ISCHEMIA (47%):         Intramyocardial microthrombi
     Branching Livedo Racemosa,        (cardiogenic shock with clean
     Splinter Hemorrhages, Digital     epicardial coronaries) + Sterile
     Cyanosis/Gangrene, Skin Ulcers.   Libman-Sacks Mitral/Aortic Valves.

  6. BILATERAL ADRENAL HEMORRHAGE / INFARCTION (13% to 26% - OFTEN MISSED.):
     * Why the Adrenal Glands? Each adrenal gland is fed by 3 arteries
       (50-60 arterioles) but drained by ONLY A SINGLE CENTRAL ADRENAL VEIN.
     * Thrombosis of that single central adrenal vein causes hemorrhagic
       venous infarction of both adrenal cortices -> Sudden Flank/Abdominal
       Pain, Hyponatremia, Hyperkalemia, & Catecholamine-Resistant Shock.
     * Lifesaving Fix: Immediate Stress-Dose IV Hydrocortisone (100 mg IV
       bolus, then 50 mg IV q6h) or Pulse IV Methylprednisolone.
========================================================================

1. The Adrenal Vein Anatomical Bottleneck (Why CAPS Causes Acute Addisonian Adrenal Crisis)¶

Why is bilateral adrenal hemorrhage/infarction a classic complication of both CAPS and HIT? - Every human adrenal gland has a rich arterial supply (superior, middle, and inferior suprarenal arteries branching into 50+ capillary plexus vessels), but all venous blood must exit through a single, solitary Central Adrenal Vein (creating a vascular "water-hammer" bottleneck rich in platelet-activating catecholamines). - When CAPS microthrombi occlude that single central adrenal vein bilaterally, venous pressure inside the adrenal cortex skyrockets until the glands rupture and hemorrhage internally (Waterhouse-Friderichsen-like hemorrhagic infarction). - Clinical Red Flags: If a patient with APS/CAPS develops new bilateral flank, back, or epigastric pain, unexplained fever, falling serum sodium (hyponatremia), rising potassium (hyperkalemia), and hypotension refractory to norepinephrine, order an immediate Abdominal CT (which shows enlarged, hyperdense edematous adrenal glands), draw a STAT random serum Cortisol and ACTH, and immediately administer 100 mg IV Hydrocortisone bolus followed by 50 mg IV every 6 hours (or make sure the patient is already receiving Pulse IV Methylprednisolone).

2. The Pulmonary Paradox: Managing Diffuse Alveolar Hemorrhage (DAH) Inside a Prothrombotic Storm¶

Up to 60 percent of CAPS patients develop acute respiratory failure from ARDS, pulmonary thromboembolism, or **non-thrombotic pulmonary capillaritis causing Diffuse Alveolar Hemorrhage (DAH: hemoptysis, ikwirakwiza alveolar zombi zinjira mu gituza CT, na a 1.5 to 3.0 g/dL ijoro ryose kugabanuka muri hemoglobine) **. - ** Nigute Indwara Yambaye ishobora gutera amaraso? ** Muri CAPS, aB2GPI antibodies na C5a gukurura immun-complexe ** pulmonary capillaritis ** (neutrophilic inflammation that necroses the alveolar capillary wall) ifatanije na microthrombose yimpyiko izamura hydrostatic capillary back-pressure kugeza selile selile zitukura zisuka mumifuka yumwuka. - ** Uburyo bwo kuyobora DAH muri CAPS: ** 1. Ako kanya wongere immunosuppression hamwe na ** Pulse IV Methylprednisolone (1,000 mg/day IV x 3 days) + Guhana kwa Plasma ya buri munsi (TPE) + IV Cyclophosphamide cyangwa Rituximab **. 2. ** Witondere Kuringaniza Anticoagulation: ** Niba kuva amaraso ya alveolar byangiza ubuzima kandi platine / fibrinogen iri hasi cyane, fata heparin ya IV idacometse mugihe gito mumasaha make mugihe utanga Pulse Steroide na Plasma Exchange, ** ariko usubukure dose / titre ya IV idakorwa na Heparin mugihe cya mikorobe ikabije ituma Hiparine ikora neza. ubwonko, umutima, n'impyiko.

Igice cya 4: Intambwe-ku-ntambwe ICU Ubuvuzi butatu bwo Gukora & Gutabara (Eculizumab & Rituximab)¶

1. Urutonde rwukuri rwa CAPS Urutonde rwubuvuzi butatu (McMaster / EULAR / International CAPS Registry Guidelines)¶

2. Second-Line Biologic Rescue for Refractory CAPS (Eculizumab na Rituximab)¶

If a CAPS patient continues to experience falling platelets, rising creatinine, new neurological deficits, or refractory microangiopathic hemolysis after 24 to 48 hours of Triple Therapy: 1. ** Guhagarika Byuzuye Byuzuye (IV Eculizumab [Soliris] cyangwa Ravulizumab [Ultomiris]): ** - Why It Works: Over 60 percent of patients with refractory CAPS harbor severe complement activation (and many carry heterozygous mutations in complement regulatory genes like CFH, CFI, or CD46 identical to atypical HUS). Eculizumab (a humanized monoclonal antibody against complement protein C5) blocks cleavage of C5 into C5a na C5b-9, arresting endothelial TMA destruction within 24 to 72 hours. - Dosing: 900 mg IV once weekly for 4 weeks, followed by 1,200 mg IV on Week 5 and every 2 weeks thereafter. - Mandatory Meningococcal Prophylaxis: Because blocking C5b-9 creates susceptibility to encapsulated Neisseria meningitidis, administer quadrivalent (MenACWY) and Serogroup B (MenB) meningococcal vaccines immediately AND start daily oral antibiotic prophylaxis (Ciprofloxacin 500 mg daily cyangwa Penicillin V 500 mg twice daily) from Day 1 of Eculizumab (do not delay Eculizumab for 2 weeks waiting for vaccine immunity). 2. **B-Cell Depletion (IV Rituximab): ** - Administer Rituximab (375 mg/m2 IV once weekly for 4 weeks, or 1,000 mg IV on Days 1 and 15) (infused after daily TPE) to eliminate CD20+ B-lymphocytes producing pathogenic antiphospholipid autoantibodies, particularly in CAPS patients with severe thrombocytopenia, diffuse alveolar hemorrhage, or cardiac/CNS involvement.

Regional emergency numbers and international CAPS registries¶

• United States and Canada: Dial 911 for any suspected multi-organ thrombosis or stroke/PE emergency. Follow the McMaster University Clinical Practice Guideline for the Diagnosis and Management of Catastrophic Antiphospholipid Syndrome (Blood Advances) and American College of Rheumatology (ACR) / ASH guidance.
• European Union and United Kingdom: Dial 112 across the EU or 999 in the UK. Follow the European Alliance of Associations for Rheumatology (EULAR) Recommendations for the Management of Antiphospholipid Syndrome in Adults (Tektonidou et al., Annals of the Rheumatic Diseases) and the British Society for Haematology (BSH) Guidelines. Clinicians worldwide can consult and log cases with the International CAPS Registry (ontocrf.costaisa.com/en/web/caps, hosted by the European Forum on Antiphospholipid Antibodies at Hospital Clínic in Barcelona, Spain, directed by Dr. Ricard Cervera).
• Australia and New Zealand: Dial 000 in Australia or 111 in New Zealand. Follow THANZ and Australian Rheumatology Association (ARA) ICU protocols for Triple Therapy and emergency Eculizumab access.

Ibibazo bikunze kubazwa¶

How is Catastrophic Antiphospholipid Syndrome (CAPS) different from regular Antiphospholipid Syndrome (APS)?¶

In classic Antiphospholipid Syndrome (APS), patients typically experience a single isolated blood clot in a large vein or artery (such as a deep vein thrombosis in one leg, a pulmonary embolism, or a stroke) or recurrent pregnancy complications, with normal function in the rest of their organs. Catastrophic Antiphospholipid Syndrome (CAPS, or Asherson's Syndrome) affects less than 1 percent of APS patients and acts like a sudden, body-wide microvascular "thrombotic storm": instead of one large clot, tiny blood clots simultaneously plug the microscopic capillaries of three or more critical organs (usually the kidneys, lungs, brain, heart, skin, and adrenal glands) within less than 7 days, accompanied by severe systemic inflammation and a falling platelet count.

Why do doctors have to give three treatments at the exact same time ("Triple Therapy") to save a patient with CAPS?¶

Historical data from the International CAPS Registry (covering over 500 patients worldwide) proved that treating CAPS with blood thinners alone or steroids alone failed in the majority of cases, because CAPS has three self-reinforcing engines: (1) Runaway fibrin and complement clotting in small vessels, (2) A fierce inflammatory cytokine storm on the blood vessel walls, and (3) High concentrations of circulating antiphospholipid autoantibodies. "Triple Therapy" attacks all three engines simultaneously: Intravenous Unfractionated Heparin stops clot propagation and inhibits complement, High-Dose IV Methylprednisolone shuts down the endothelial cytokine storm, and Daily Therapeutic Plasma Exchange (Plasmapheresis) and/or IVIG physically removes and neutralizes the autoantibodies, cutting mortality from over 75 percent down to roughly 30 percent.

Why can't nurses and doctors use the standard aPTT blood test to monitor intravenous Heparin in a patient with CAPS?¶

Patients with CAPS almost always have a circulating antiphospholipid antibody called a "Lupus Anticoagulant" (LA). Paradoxically, although a Lupus Anticoagulant causes severe blood clotting inside the human body, inside a glass laboratory test tube it binds to the phospholipid reagents used to run the standard activated Partial Thromboplastin Time (aPTT) test, artificially making the patient's baseline aPTT look prolonged (for example, 85 seconds) before a single drop of heparin is even given. If a clinician uses the aPTT to titrate the heparin drip, they will mistakenly think the patient's blood is "already too thin" and turn the heparin drip down to sub-therapeutic levels while the patient clots to death. Instead, IV Heparin in CAPS must always be monitored with a chromogenic Anti-Factor Xa (Anti-Xa) blood level (targeting 0.3 to 0.7 IU/mL), which is unaffected by the Lupus Anticoagulant.

Kuki CAPS ikunze gutera ikibazo gitunguranye, cyangiza ubuzima bwa Adrenal Crisis (Shock Addisonian)?¶

Each of your two adrenal glands (which sit on top of the kidneys and produce life-sustaining cortisol and aldosterone) receives blood through dozens of small arteries, but drains all of its blood out through one single Central Adrenal Vein. During a CAPS thrombotic storm, micro-clots easily plug that single draining adrenal vein on both sides. With the exit vein blocked, arterial blood backs up inside both adrenal glands until they swell and rupture internally (bilateral adrenal hemorrhage and infarction). This wipes out the body's cortisol production overnight, causing severe flank or stomach pain, low sodium, high potassium, and fatal low blood pressure unless treated immediately with high-dose intravenous corticosteroids (Methylprednisolone or Hydrocortisone).

Ni ukubera iki abarwayi bafite Triple-positif APS cyangwa CAPS ibanza batagomba guhindurwa bava i Warfarin bajya mu binini bigezweho bya Anticoagulant (DOAC) nka Rivaroxaban cyangwa Apixaban?¶

Ibigeragezo byinshi byateganijwe (harimo na TRAPS na ASTRO-APS) byahagaritswe hakiri kare nyuma yo kubona ko abarwayi bafite syndrome ya "Triple-Positive" Antiphospholipid Syndrome (nziza kuri Lupus Anticoagulant, Anti-Cardiolipin, na Anti-Beta-2-Glycoprotein-I) bafashe Direct Oral Antagags nka Arican ya Antaban. Inshuro 4 kugeza kuri 7 umuvuduko mwinshi wa arterial stroke hamwe nindwara z'umutima kurusha abarwayi bafata Warfarin. Guhagarika ikintu kimwe gusa (Factor Xa cyangwa Factor IIa) hamwe na DOAC akenshi ntibihagije kugirango uhagarike trombine nini kandi wuzuze ibintu byatewe na antibodiyite antifosifolipide eshatu, kandi kuva muri Warfarin ukajya muri DOAC ni imbarutso ya APS ikaze ya Catastropique.

Inkomoko nubuyobozi¶

• ** Amashuri makuru ya kaminuza ya McMaster / Amabwiriza y’ubuvuzi ya ASH (Legault K et al., * Iterambere ry’amaraso *): **
• European Alliance of Associations for Rheumatology (EULAR, Tektonidou MG et al., Annals of the Rheumatic Diseases): EULAR Recommendations for the Management of Antiphospholipid Syndrome in Adults (Contraindication of DOACs in Triple-Positive APS and CAPS Management).
• International Consensus Statement on Classification Criteria and Treatment Guidelines for Catastrophic Antiphospholipid Syndrome (Asherson RA, Cervera R, et al., Lupus / Journal of Rheumatology): Preliminary Classification Criteria for Definite and Probable CAPS and Analysis of 500+ Patients from the International CAPS Registry.
• British Society for Haematology (BSH, Arachchillage DRJ et al.): Guidelines on the Investigation and Management of Antiphospholipid Syndrome and Catastrophic APS.
• New England Journal of Medicine (NEJM) Review (Garcia D, Erkan D): Diagnosis and Management of the Antiphospholipid Syndrome and Complement Inhibition in CAPS.

Kuyobora¶

• Adrenal crisis and Addison's disease emergency injection
• Heparin-induced thrombocytopenia (HIT) and VITT: 50 percent platelet drop on Day 5 to 10 and Argatroban
• Eclampsia seizures, HELLP syndrome, postpartum preeclampsia, and magnesium triage
• Sepsis na septique
• Imibare yihutirwa ukurikije igihugu